<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> immunotherapy broadly includes active immunization, as in the use of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccines, passive immunization, such as the use of adoptive cell therapy and antibodies that modulate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> function, and immunostimulation, using antibodies and small molecules to treat <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> by activating or unleashing an endogenous immune response against <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>Currently, &gt;100 different monoclonal antibodies are in use or under evaluation for use as therapeutic agents in various <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Active stimulation of the host's immune system holds promise for achieving durable remission of malignant disease and represents a nontoxic method of therapy if <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific effector cells can be selectively targeted </plain></SENT>
<SENT sid="3" pm="."><plain>However, no active-specific treatment strategy (i.e., a therapeutic <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccine) has yet found its way into the clinical armamentarium, although several promising recent reports suggest that, for follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0012125'>prostate cancer</z:hpo>, and <z:hpo ids='HP_0002861'>melanoma</z:hpo>, clinical benefit was shown for the first time in randomized trials with a vaccine approach </plain></SENT>
<SENT sid="4" pm="."><plain>Here, we report on the key findings of the Third Tegernsee Conference on Immunotherapy of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> (Feldafing, Germany, July 2-4, 2009) and provide short commentaries on data presented at this meeting regarding the future role of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> vaccines, recent developments in adoptive cellular therapy, ways to improve immunotherapeutic treatment modalities (e.g., by manipulating the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> microenvironment), and some novel targeted therapies that are well advanced in clinical testing, <z:hpo ids='HP_0000001'>all</z:hpo> of which have implications for future <z:hpo ids='HP_0002664'>oncology</z:hpo> practice </plain></SENT>
</text></document>